Compare · ABT vs ANIX
ABT vs ANIX
Side-by-side comparison of Abbott Laboratories (ABT) and Anixa Biosciences Inc. (ANIX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABT and ANIX operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABT is the larger of the two at $200.95B, about 1613.7x ANIX ($124.5M).
- ABT has been more active in the news (8 items in the past 4 weeks vs 3 for ANIX).
- ABT has more recent analyst coverage (25 ratings vs 2 for ANIX).
- Company
- Abbott Laboratories
- Anixa Biosciences Inc.
- Price
- -
- -
- Market cap
- $200.95B
- $124.5M
- 1M return
- -
- +5.81%
- 1Y return
- -
- +22.15%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 8
- 3
- Recent ratings
- 25
- 2
Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
Anixa Biosciences Inc.
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain viral protein functions of the virus. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. It has a collaboration agreement with MolGenie GmbH to discover and develop anti-viral drug candidates against COVID-19. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was founded in 1982 and is based in San Jose, California.
Latest ABT
- Abbott receives FDA authorization for world's first dual glucose-ketone sensing technology for people with diabetes
- Abbott Laboratories filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Abbott reaches agreements to resolve a portion of litigation involving its specialty formulas for preterm infants
- Abbott and NACHC launch nationwide Food for Health initiative to make nutritious food a core part of healthcare
- EXECUTIVE VICE PRESIDENT Morrone Louis H. sold $642,506 worth of Common shares without par value (5,850 units at $109.83), decreasing direct ownership by 8% to 70,724 units (SEC Form 4)
- Abbott Labs upgraded by Wolfe Research with a new price target
- Abbott and Big Ten bring back 'We Give Blood' as U.S. faces blood supply crisis
- Abbott and Google launch first-of-its-kind partnership to transform everyday health through glucose insights and AI
- SEC Form 10-Q filed by Abbott Laboratories
- FDA Approves Freenome’s SimpleScreen™ CRC Blood-Based Screening Test; Abbott to Commercialize in the U.S.
Latest ANIX
- Anixa Biosciences to Present at the 2026 Cantor Fitzgerald Global Healthcare Conference Highlighting its Breast Cancer Vaccine and Ovarian Cancer CAR-T Therapy
- Anixa Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference
- Chief Executive Officer Kumar Amit bought $17,350 worth of shares (5,000 units at $3.47), increasing direct ownership by 0.77% to 657,000 units (SEC Form 4)
- Director Baskies Arnold M exercised 6,000 shares at a strike of $3.13 and covered exercise/tax liability with 5,428 shares, increasing direct ownership by 0.42% to 135,572 units (SEC Form 4)
- Chief Executive Officer Kumar Amit bought $17,200 worth of shares (5,000 units at $3.44), increasing direct ownership by 0.77% to 652,000 units (SEC Form 4)
- Chief Executive Officer Kumar Amit bought $10,744 worth of shares (3,188 units at $3.37), increasing direct ownership by 0.50% to 647,000 units (SEC Form 4)
- Chief Executive Officer Kumar Amit bought $11,190 worth of shares (3,000 units at $3.73), increasing direct ownership by 0.47% to 643,812 units (SEC Form 4)
- Chief Executive Officer Kumar Amit bought $17,300 worth of shares (5,000 units at $3.46), increasing direct ownership by 0.79% to 640,812 units (SEC Form 4)
- Director Titterton Lewis H Jr bought $41,640 worth of shares (12,000 units at $3.47), increasing direct ownership by 1% to 986,967 units (SEC Form 4)
- Director Titterton Lewis H Jr bought $9,174 worth of shares (2,797 units at $3.28), increasing direct ownership by 0.29% to 974,967 units (SEC Form 4)